Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen (Nasdaq: XGN) management will participate in investor conferences and meet with investors in New York on November 11 and 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Exagen (Nasdaq: XGN) management will participate in investor conferences and meet with investors in New York on November 11 and 17, 2026.
The November 11 event is Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum, with the Innovative Diagnostics for Attractive Immunology Applications panel at 10:30am ET. Management will also attend Craig-Hallum’s Alpha Select Conference on November 17.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in and meet with investors at the following investor conferences:
Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum – New York, NY
Date: November 11, 2026
Panel: Innovative Diagnostics for Attractive Immunology Applications at 10:30am ET
Craig-Hallum's Alpha Select Conference – New York, NY
Date: November 17, 2026
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a specialized diagnostics company with an autoimmune platform that empowers physicians to make more confident decisions, earlier. Its flagship test, AVISE® CTD, provides diagnostic clarity in complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's disease. Based in San Diego County, California, Exagen operates a CLIA-certified, CAP-accredited rheumatology laboratory delivering precise, timely results to physicians and partners across healthcare and biopharma. Through ongoing research and innovation, Exagen is committed to advancing care for autoimmune disease.
For more information, visit Exagen.com or follow Exagen on LinkedIn.
Investors:
Tina Jacobsen, CFA
IR@exagen.com
